Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Xagenic logo — Empowering clinicians with rapid, near-patient molecular tes...

Xagenic

Empowering clinicians with rapid, near-patient molecular testing for improved patient care and reduced healthcare costs.

Founded 2010 Series B Total: $63.28M Biotechnology, Health Care +1

General Information

Company Name Xagenic
Founded Year 2010
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Xagenic. To contact Xagenic, visit xagenic.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Xagenic compare?

A PDF of Xagenic and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Xagenic soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Xagenic

Xagenic, based in Toronto, Canada, is a trailblazer in molecular diagnostics, dedicated to developing cutting-edge technology for rapid, near-patient diagnostic testing. Their mission is to equip clinicians with the ability to make timely treatment decisions during the initial patient consultation, ultimately enhancing patient care and reducing healthcare expenses. Xagenic’s innovative approach enables swift, enzyme-free detection of nucleic acids from clinical samples. The company has introduced a user-friendly, fully automated technology platform tailored for widespread diagnostic testing outside traditional clinical laboratories. Their focus is on the development of infectious disease tests capable of rapidly identifying various analytes, providing clinically actionable results in scenarios where fast test turnaround is critical. Founded in 2010, Xagenic operates within the biotechnology, healthcare, and medical devices sectors. Notably, the company received a $15.00M Series B investment on 09 July 2015 from Domain Associates, CTI Life Sciences Fund, The Ontario Capital Growth, and BDC Healthcare Venture, signifying recognized support from reputable investors in the industry.

Business keywords: molecular diagnostics, rapid testing, point-of-care, infectious disease, clinical samples, decentralized testing, enzyme-free detection, near-patient testing, clinician empowerment

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $15.00M 4
Domain Associates CTI Life Sciences Fund The Ontario Capital Growth
Domain Associates, CTI Life Sciences Fund +2
09 Jul 2015
Series B $25.50M 3
Domain Associates
Domain Associates, CTI Capital +1
14 Jul 2014
Venture Round $9.59M -
10 Dec 2013
Grant $990.00K 1
Government of Canada
Government of Canada
19 Feb 2013
Series A $10.00M 4
CTI Life Sciences Fund The Ontario Capital Growth
CTI Life Sciences Fund, The Ontario Capital Growth +2
30 Jan 2012
Seed Round Undisclosed 1
MaRS IAF
MaRS IAF
07 Feb 2011
Seed Round $2.20M 1
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners
01 Jan 2010

Xagenic Alternatives & Competitors

View All Alternatives
Xagenic vs
STAT-Dx
STAT-Dx

Our Mission is to Support Timely, Efficient Patient Care, while Optimizing Laboratory and Hospital P...

Series C
18 employees
Biotechnology, Health Care
Xagenic vs
EMPE Diagnostics
EMPE Diagnostics Sweden

Confirmatory precision diagnostics for tuberculosis (MDR/XDR-TB) within 3 h even at resource-limited...

Series A
27 employees
Biotechnology, Health Care
Xagenic vs
Avails Medical, Inc.
Avails Medical, Inc. United States

Avails Medical, Inc. - Affordable & Rapid Antibiotic Susceptibility Testing for clinical laboratorie...

Grant
51 employees
Health Care, Medical Devices
Compare Xagenic vs Avails Medical, Inc.
View all alternatives

FAQ About Xagenic

Empowering clinicians with rapid, near-patient molecular testing for improved patient care and reduced healthcare costs.
Xagenic was founded in 2010.
Xagenic operates in Biotechnology, Health Care and Medical Devices. Its work centres on molecular diagnostics, rapid testing, point-of-care and infectious disease.
Xagenic has completed 7 funding rounds, raising a total of $63.28M. The latest funding stage is Series B.
Top alternatives and competitors to Xagenic include STAT-Dx, EMPE Diagnostics, Avails Medical, Inc., Lucira Health, Microplate Dx Limited. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Xagenic and STAT-Dx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Xagenic, https://bouncewatch.com/company/xagenic, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes